---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-032517"
form_type: "8-K"
ticker: "MGRX"
cik: "0001938046"
company_name: "MANGOCEUTICALS, INC."
filed_at: "2024-08-15T23:59:59+00:00"
generated_at: "2026-05-31T09:07:16.061267+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MangoRx reports H1 2024 revenue up 56% YoY to $377K; shareholders' equity jumps 1,685% to $13.8M

## Summary
- Revenue $377,258 for six months ended June 30, 2024, up 55.92% from $241,959 YoY; gross profit $217,190 (+50.48%).
- Shareholders' equity increased to $13,829,445 vs $774,754 at Dec 31, 2023 (+1,685%), largely due to Intramont patent portfolio acquisition in April 2024.
- Company plans to launch compounded ODT GLP-1 inhibitors (Semaglutide/Tirzepatide) for weight loss and hormone therapy MOJO (Enclomiphene/pregnenolone).
- CEO highlights launch of DEA-approved telemedicine operating system.

## SEC filing metadata
- accession: 0001493152-24-032517
- form_type: 8-K
- ticker: MGRX
- cik: 0001938046
- company_name: MANGOCEUTICALS, INC.
- filed_at: 2024-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1938046/000149315224032517/0001493152-24-032517-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1938046/000149315224032517/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-032517
- JSON: https://secwatch.observer/filing/0001493152-24-032517.json
- Plain text: https://secwatch.observer/filing/0001493152-24-032517.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.